Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Pulse Biosciences (PLSE) EBITDA (2020 - 2025)

Pulse Biosciences has reported EBITDA over the past 6 years, most recently at -$19.4 million for Q3 2025.

  • Quarterly results put EBITDA at -$19.4 million for Q3 2025, down 52.88% from a year ago — trailing twelve months through Sep 2025 was -$74.7 million (down 61.99% YoY), and the annual figure for FY2025 was $72.8 million, up 235.86%.
  • EBITDA for Q3 2025 was -$19.4 million at Pulse Biosciences, down from -$19.2 million in the prior quarter.
  • Over the last five years, EBITDA for PLSE hit a ceiling of -$9.2 million in Q4 2022 and a floor of -$19.4 million in Q4 2024.
  • Median EBITDA over the past 5 years was -$14.3 million (2021), compared with a mean of -$14.4 million.
  • Biggest five-year swings in EBITDA: soared 43.26% in 2023 and later tumbled 68.39% in 2025.
  • Pulse Biosciences' EBITDA stood at -$15.4 million in 2021, then soared by 40.34% to -$9.2 million in 2022, then decreased by 29.75% to -$11.9 million in 2023, then crashed by 62.45% to -$19.4 million in 2024, then changed by 0.0% to -$19.4 million in 2025.
  • The last three reported values for EBITDA were -$19.4 million (Q3 2025), -$19.2 million (Q2 2025), and -$16.8 million (Q1 2025) per Business Quant data.